▲ +1.96% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Pfenex in the last 3 months. The average price target is $13.00, with a high forecast of $13.00 and a low forecast of $13.00. The average price target represents a 1.96% upside from the last price of $12.75.
The current consensus among 4 contributing investment analysts is to hold stock in Pfenex. This rating has held steady since August 2019, when it changed from a Buy consensus rating.
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.